Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources

GENE - CHEMICAL INTERACTIONS REPORT

RGD ID: 1317784
Species: Homo sapiens
RGD Object: Gene
Symbol: CYP2C9
Name: cytochrome P450 family 2 subfamily C member 9
Acc ID: CHEBI:10033
Term: warfarin
Definition: A racemate comprising equal amounts of (R)- and (S)-warfarin. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.
Chemical ID: MESH:D014859
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction is comprised of a complex set of reactions and/or regulatory events, possibly involving additional chemicals and/or gene products.
Object SymbolQualifierEvidenceWithReferenceSourceNotesOriginal Reference(s)
CYP2C9affects abundanceEXP 6480464CTDCYP2C9 gene polymorphism affects the abundance of WarfarinPMID:25986145
CYP2C9affects hydrolysisEXP 6480464CTDCYP2C9 gene polymorphism affects the hydrolysis of WarfarinPMID:9698079
CYP2C9affects hydroxylationEXP 6480464CTDCYP2C9 protein affects the hydroxylation of WarfarinPMID:10613612
CYP2C9affects metabolic processingEXP 6480464CTDCYP2C9 enhancer polymorphism affects the metabolism of Warfarin; CYP2C9 gene affects the metabolism of Warfarin; CYP2C9 gene polymorphism affects the metabolism of Warfarin; CYP2C9 protein affects the metabolism of WarfarinPMID:11307788 PMID:12621390 PMID:14586384 PMID:14676821 PMID:17332144 PMID:20073138 PMID:27539372
CYP2C9affects response to substanceEXP 6480464CTDCYP2C9 affects the susceptibility to Warfarin; CYP2C9 alternative form affects the susceptibility to Warfarin; CYP2C9 gene affects the susceptibility to Warfarin; CYP2C9 gene mutant form affects the susceptibility to Warfarin; CYP2C9 gene polymorphism affects the susceptibility to Warfarin; CYP2C9 gene SNP affects the susceptibility to Warfarin; CYP2C9 polymorphism affects the susceptibility to Warfarin; CYP2C9 protein affects the susceptibility to Warfarin; CYP2C9 protein polymorphism affects the susceptibility to Warfarin; CYP2C9 SNP affects the susceptibility to Warfarin; CYP2C9 SNP affects the susceptibility to Warfarin analogPMID:11127854 PMID:11307788 PMID:14656880 PMID:14676821 PMID:14691573 PMID:15001971 PMID:15050794 PMID:15100169 PMID:15284536 PMID:15371982 PMID:15900281 PMID:15900282 PMID:15940194 PMID:15952022 PMID:16432637 PMID:16611750 PMID:16676068 PMID:16708125 PMID:16847429 PMID:16878445 PMID:16890578 PMID:16960144 PMID:17048007 PMID:17049586 PMID:17111199 PMID:17387222 PMID:17456829 PMID:17496169 PMID:17510308 PMID:17672075 PMID:17764537 PMID:17895500 PMID:17955230 PMID:18034618 PMID:18370846 PMID:18429757 PMID:18535201 PMID:18542936 PMID:18570163 PMID:18574025 PMID:18698879 PMID:18756910 PMID:18776969 PMID:18836275 PMID:19207028 PMID:19300499 PMID:19567378 PMID:19745563 PMID:19752777 PMID:19998810 PMID:20072124 PMID:20339978 PMID:20354686 PMID:20375999 PMID:20386359 PMID:20442691 PMID:20615525 PMID:20637959 PMID:20653674 PMID:20677151 PMID:20833655 PMID:20842355 PMID:20854800 PMID:20884456 PMID:21110192 PMID:21228733 PMID:21261182 PMID:21270790 PMID:21320153 PMID:21321468 PMID:21326313 PMID:21428138 PMID:21451434 PMID:21562147 PMID:21590310 PMID:21635147 PMID:21639946 PMID:21681008 PMID:21713378 PMID:21786578 PMID:21911247 PMID:22040439 PMID:22161100 PMID:22198820 PMID:22248286 PMID:22266406 PMID:22274142 PMID:22528326 PMID:22533669 PMID:22594507 PMID:22855348 PMID:22907842 PMID:22990331 PMID:23061746 PMID:23159229 PMID:23167228 PMID:23183958 PMID:23208322 PMID:23276529 PMID:23279643 PMID:23376925 PMID:23602689 PMID:23688605 PMID:23710884 PMID:23800980 PMID:23990957 PMID:24474498 PMID:24601977 PMID:24750390 PMID:24956244 PMID:24966969 PMID:24978953 PMID:25042728 PMID:25075423 PMID:25298588 PMID:25312789 PMID:25499099 PMID:25521356 PMID:25652102 PMID:25699611 PMID:25747538 PMID:25866574 PMID:25904339 PMID:25946405 PMID:26223945 PMID:26418980 PMID:26502504 PMID:26568290 PMID:26644206 PMID:26940072 PMID:26996562 PMID:27055637 PMID:27313202 PMID:27488176 PMID:27581200 PMID:27622442 PMID:27632229 PMID:27743182 PMID:28079798 PMID:28083852 PMID:28262345 PMID:28401802 PMID:28550460 PMID:28686080 PMID:28689179 PMID:28867752 PMID:29182754 PMID:30647445 PMID:30883300 PMID:31064211 PMID:31173123 PMID:31395958 PMID:31854268 PMID:31869433 PMID:34382722 PMID:34729928 PMID:35818222 PMID:36476275 PMID:36789833
CYP2C9decreases activityEXP 6480464CTDWarfarin results in decreased activity of CYP2C9 proteinPMID:18420780
CYP2C9decreases hydroxylationEXP 6480464CTDCYP2C9 gene polymorphism results in decreased hydroxylation of WarfarinPMID:11455026
CYP2C9decreases metabolic processingEXP 6480464CTDCYP2C9 gene polymorphism results in decreased metabolism of WarfarinPMID:20073138
CYP2C9decreases response to substanceEXP 6480464CTDCYP2C9 gene polymorphism results in decreased susceptibility to WarfarinPMID:18030307 PMID:18034619
CYP2C9increases hydrolysisEXP 6480464CTDCYP2C9 protein results in increased hydrolysis of WarfarinPMID:9698079
CYP2C9increases hydroxylationEXP 6480464CTDCYP2C9 protein results in increased hydroxylation of WarfarinPMID:11455026 PMID:12433797 PMID:12637241 PMID:14661864 PMID:20429590 PMID:23302640 PMID:25986145 PMID:26255664 PMID:9241660 PMID:9522436
CYP2C9increases metabolic processingEXP 6480464CTDCYP2C9 protein results in increased metabolism of WarfarinPMID:12464242 PMID:16878445 PMID:18756910 PMID:19082874 PMID:19300499 PMID:19408964 PMID:19715737
CYP2C9increases response to substanceEXP 6480464CTDCYP2C9 gene mutant form results in increased susceptibility to Warfarin; CYP2C9 gene polymorphism results in increased susceptibility to Warfarin; CYP2C9 protein results in increased susceptibility to Warfarin; CYP2C9 results in increased susceptibility to WarfarinPMID:11794436 PMID:17049586 PMID:17111199 PMID:17387222 PMID:17496169 PMID:18542936 PMID:19899329 PMID:20420818 PMID:25994031 PMID:26255664
CYP2C9multiple interactionsEXP 6480464CTD10-hydroxywarfarin inhibits the reaction [[CYP2C9 protein results in increased hydroxylation of Warfarin] which results in increased chemical synthesis of 7-hydroxywarfarin]; 4'-hydroxywarfarin inhibits the reaction [[CYP2C9 protein results in increased hydroxylation of Warfarin] which results in increased chemical synthesis of 7-hydroxywarfarin]; 6-hydroxywarfarin inhibits the reaction [[CYP2C9 protein results in increased hydroxylation of Warfarin] which results in increased chemical synthesis of 7-hydroxywarfarin]; 7-hydroxywarfarin inhibits the reaction [[CYP2C9 protein results in increased hydroxylation of Warfarin] which results in increased chemical synthesis of 6-hydroxywarfarin]; 8-hydroxywarfarin inhibits the reaction [[CYP2C9 protein results in increased hydroxylation of Warfarin] which results in increased chemical synthesis of 7-hydroxywarfarin]; [[Ticrynafen results in decreased activity of CYP2C9 protein] which affects the metabolism of Warfarin analog] which affects the abundance of 7-hydroxywarfarin; [CYP2C9 gene polymorphism affects the metabolism of Warfarin] which affects the abundance of 10-hydroxywarfarin; [CYP2C9 gene polymorphism affects the metabolism of Warfarin] which affects the abundance of 4'-hydroxywarfarin; [CYP2C9 gene polymorphism affects the metabolism of Warfarin] which affects the abundance of 6-hydroxywarfarin; [CYP2C9 gene polymorphism affects the metabolism of Warfarin] which affects the abundance of 7-hydroxywarfarin; [CYP2C9 protein results in increased hydroxylation of Warfarin] which results in increased chemical synthesis of 6-hydroxywarfarin; [CYP2C9 protein results in increased hydroxylation of Warfarin] which results in increased chemical synthesis of 7-hydroxywarfarin; [CYP2C9 protein results in increased metabolism of Warfarin] which results in increased chemical synthesis of 6-hydroxywarfarin; [CYP2C9 protein results in increased metabolism of Warfarin] which results in increased chemical synthesis of 7-hydroxywarfarin; [Ticrynafen results in decreased activity of CYP2C9 protein] which affects the metabolism of Warfarin analog; [Warfarin binds to and results in increased activity of NR1I2 protein] which results in increased expression of CYP2C9 mRNA; Benzbromarone inhibits the reaction [CYP2C9 protein affects the metabolism of Warfarin]; CYP2C9 gene polymorphism affects the reaction [Vitamin K affects the susceptibility to Warfarin]; CYP2C9 gene polymorphism affects the susceptibility to and affects the metabolism of Warfarin; Simvastatin affects the reaction [CYP2C9 polymorphism affects the susceptibility to Warfarin]; Warfarin inhibits the reaction [CYP2C9 protein affects the metabolism of Diclofenac]PMID:10613612 PMID:16081671 PMID:19408964 PMID:20429590 PMID:20735727 PMID:22594507 PMID:26469104 PMID:27462768 PMID:27539372 PMID:31854189
Go Back to source page   Continue to Ontology report